Company Insights

LAZ customer relationships

Explore interactive graphBrowse insights index

LAZ customers relationship map

Lazard Ltd (LAZ) — Client Relationships and What They Mean for Investors

Lazard monetizes through financial advisory mandates and asset management fees: the firm sells bespoke M&A, restructuring and capital‑markets advice to large corporates, private equity and governments, while generating recurring but contractually short‑duration revenue from institutional and high‑net‑worth asset management mandates. Advisory engagements drive headline fees and episodic revenue; asset management supplies stable AUM fees but remains terminable on short notice. For investor diligence, this profile implies high revenue volatility tied to mandate flow and deal cycles, offset by broad geographic reach and a diversified client base. For a concise operational view and ongoing monitoring, visit https://nullexposure.com/.

How Lazard wins work and how that translates to revenue

Lazard operates as a boutique global advisor: it competes for high‑value, episodic mandates (M&A, restructuring, capital raises) while running an asset management arm that serves institutions and wealthy individuals. The company’s contracts are short‑term and engagement‑by‑engagement, making revenue lumpy but margins high on closed mandates. Public disclosures confirm no single client drives more than 10% of segment revenue, signaling client concentration is immaterial for materiality but the business remains sensitive to deal flow and macro transaction markets.

Operating constraints that matter to investors

  • Contracting posture: short‑term. Investment advisory contracts are generally terminable on short notice and most revenue comes from individual, negotiated engagements (company filings, FY2024–FY2025).
  • Client mix: institutional tilt but meaningful HNW exposure. About 82% of AUM is institutional; roughly 18% from individuals/family offices (FY2024 AUM disclosure).
  • Geographic breadth: truly global. Revenue and operations span Americas, EMEA, and Asia‑Pacific, supporting resiliency to single‑market shocks.
  • Materiality: individual clients are immaterial. No single client exceeded 10% of segment net revenue for FY2022–FY2024.
  • Role: service provider. Lazard predominantly serves as advisor and asset manager, not as principal buyer, with active mandates across Financial Advisory and Asset Management.
  • Relationship stage: active. The firm reported hundreds of clients contributing meaningful revenue and a rising pipeline of large deals (FY2024–FY2025 earnings commentary).

Complete client and mandate roll‑call (excerpts from public reporting)

Below is a compact roll‑call of every relationship captured in public sources for investor review. Each line is a one‑sentence summary with the cited source.

  • Mars — Lazard advised on Kellanova’s $35.9bn sale to Mars (InsiderMonkey, Q4 2025 earnings call transcript, Mar 2026).
  • Mars (duplicate entry) — Listed again in Q4 2025 commentary (InsiderMonkey, Mar 2026).
  • SGTX (Sigilon) — Lazard acted as lead financial advisor to Sigilon in its Lilly transaction (Building Indiana, FY2023).
  • Ferrero — Lazard advised on Ferrero’s acquisition of W.K. Kellogg, cited among high‑profile mandates (TS2.tech, FY2025).
  • KDP (Keurig Dr Pepper) — Lazard advised on KDP’s $23bn acquisition of JDE Peet’s and the planned separation (InsiderMonkey, Q3 2025).
  • Keurig Dr. Pepper (duplicate) — Same KDP deal referenced in earnings commentary (InsiderMonkey, Q3 2025).
  • Mallinckrodt Pharmaceuticals — Lazard listed as advisor on Mallinckrodt’s $6.7bn combination with Endo (InsiderMonkey, FY2025).
  • KDP (duplicate from TS2.tech) — KDP’s transaction referenced also in strategic activity summary (TS2.tech, FY2025).
  • Nexus Capital Management — Lazard advised on the closing of Nexus Capital Management Fund IV (InsiderMonkey, Q3 2025).
  • Norvestor — Lazard advised Norvestor on a continuation fund (InsiderMonkey, Q3 2025).
  • Keurig Dr Pepper (duplicate) — Additional references to KDP in Q3 commentary (TS2.tech, FY2025).
  • Saks Global — Lazard involved in corporate restructuring assignments including Saks Global (InsiderMonkey, Q3 2025).
  • LivePerson — Lazard referenced on restructuring and M&A mandates for LivePerson (TS2.tech, FY2025).
  • LPSN (LivePerson) — Lazard acted as financial advisor to LivePerson in announced M&A (SoundHound press release; Marketscreener/GlobeNewsWire, FY2026).
  • Thoughtworks (TWKS) — Lazard acted as financial advisor to the special committee in Thoughtworks privatization (AlternativesWatch, FY2024).
  • BTU (Peabody/Navajo) — Lazard retained to help locate buyers for Navajo Generating Station assets (AZCentral reporting, FY2017).
  • AbbVie — Lazard listed among advisors on ImmunoGen sale and other healthcare deals (CityBiz reporting, FY2024).
  • IX (OCP/SWAT) — Lazard served as financial advisor to OCP and SWAT in the IX transaction (AI Journ, FY2026).
  • LPSN (duplicate) — Lazard confirmed advisor role in LivePerson deal filings and press releases (SoundHound/GlobeNewsWire, FY2026).
  • Biogen — Lazard advised on Biogen’s acquisition of Reata Pharmaceuticals among healthcare mandates (CityBiz, FY2024).
  • CVS Health — Lazard advised on CVS’s acquisition of Oak Street Health (CityBiz, FY2024).
  • WALD (Waldencast) — Board retained Lazard as financial advisor to evaluate strategic pathways (Quiver Quant, FY2025).
  • Danaher — Lazard listed on transactions including Abcam sale to Danaher (CityBiz, FY2024).
  • FRGAP (Franchise Group) — Lazard served as investment banker to a first‑lien ad hoc group in the Franchise Group bankruptcy (PetAge reporting, FY2024).
  • Gilead — Lazard included on healthcare advisory list including CymaBay acquisition by Gilead (CityBiz, FY2024).
  • FLXN (Flexion) — Lazard acted as lead financial advisor to Flexion in Pacira transaction (Yahoo Finance, FY2021).
  • LPSN (Marketscreener) — Lazard Frères & Co. LLC acted as financial advisor to LivePerson in acquisition filings (Marketscreener, FY2026).
  • VSNTV (Versant Media/SportsEngine) — Versant hired Lazard to explore sale of SportsEngine (Investing.com/Bloomberg cited, FY2026).
  • Odyssey Investment Partners — Lazard advised Odyssey on a continuation fund (InsiderMonkey, Q4 2025).
  • Sanofi — Lazard listed among advisors on multiple healthcare transactions, including Inhibrx sale (CityBiz, FY2024).
  • Vertex — Lazard advised on Vertex’s $4.9bn acquisition of Alpine Immune Sciences (CityBiz, FY2024).
  • VRTX (duplicate) — Same Vertex listing in healthcare mandates (CityBiz, FY2024).
  • IMXI (Intermex) — Lazard Frères & Co. served as financial advisor to Intermex’s strategic alternatives committee (CityBiz, FY2025).
  • LPSN (GlobeNewsWire) — Corporate press releases confirm Lazard’s advisory role to LivePerson (GlobeNewsWire, FY2026).
  • EIR Partners Fund III — Lazard advised on closing of EIR Partners Fund III (InsiderMonkey, Q4 2025).
  • CVCCF (CVC Capital Partners) — Lazard advised CVC Capital Partners on multiple engagements (InsiderMonkey, Q4 2025).
  • Vir Biotechnology (VIR) — Lazard acted as Vir’s exclusive financial advisor on a strategic collaboration (PR Newswire, FY2026).
  • Wald (duplicate) — Board retained Lazard for strategic advice on Waldencast (Quiver Quant, FY2025).
  • THS (TreeHouse Foods) — Lazard cited on Invest Industrial’s $2.9bn acquisition of TreeHouse Foods (InsiderMonkey, Q4 2025).
  • TreeHouse Foods (duplicate) — Same Invest Industrial engagement (InsiderMonkey, FY2026).
  • Reata Pharmaceuticals — Lazard listed on healthcare M&A advisory roster (CityBiz, FY2024).
  • Alpine Immune Sciences — Lazard advised on Alpine Immune Sciences sale (CityBiz, FY2024).
  • Boston Celtics (Sixth Street consortium) — Lazard listed among advisers on a consortium investment in the Boston Celtics (InsiderMonkey, FY2025).
  • Galderma — Lazard included on Galderma IPO advisory mentions (CityBiz, FY2024).
  • CymaBay Therapeutics — Lazard listed on CymaBay advisory mentions (CityBiz, FY2024).
  • CEG / Constellation Energy — Lazard noted on Constellation’s acquisition of Calpine (InsiderMonkey, Q4 2025).
  • Orsted (DNNGY) — Lazard engaged on capital‑structure and debt raising assignments including Orsted (InsiderMonkey, Q4 2025).
  • Talen Energy (TLN) — Lazard engaged on Caithness Energy asset sale to Talen Energy (InsiderMonkey, Q3 2025).
  • Lighthouse (LGHT) — Lazard handled capital structure and debt raising mandates including Lighthouse (InsiderMonkey, Q4 2025).
  • Inhibrx (INBX) — Lazard listed on Inhibrx advisory mentions (CityBiz, FY2024).
  • Superior Industries (SSUP) — Lazard engaged on liability management and restructuring for Superior Industries (InsiderMonkey, Q4 2025).
  • Abcam (ABC) — Lazard advised on Abcam’s sale to Danaher (CityBiz, FY2024).
  • Sixth Street (TSLX) — Sixth Street cited among consortium investors where Lazard reported involvement (InsiderMonkey, FY2025).
  • CFHLF / CityFibre — Lazard engaged in corporate restructuring assignments with CityFibre (InsiderMonkey, Q3 2025).
  • Anthology — Lazard participated in restructuring mandates including Anthology (InsiderMonkey, Q3 2025).
  • Caithness Energy — Lazard advised on multiple Caithness transactions, including an asset sale (InsiderMonkey, Q3 2025).
  • Ferrero (duplicate) — Ferrero’s W.K. Kellogg acquisition appears in Lazard materials (InsiderMonkey/TS2.tech, FY2025).
  • JDE Peet’s (JDEP) — Lazard referenced on KDP‑JDE Peet’s transaction (InsiderMonkey, Q3 2025).
  • Morrisons — Lazard advised on capital structure and capital raises for Morrisons (InsiderMonkey, Q3 2025).
  • Pacific Avenues Fund II — Lazard advised on closing of Pacific Avenues Fund II (InsiderMonkey, Q3 2025).
  • Tennant Holdings — Lazard advised on capital raises for Tennant Holdings (InsiderMonkey, Q3 2025).
  • W.K. Kellogg — Lazard advised on the Ferrero acquisition of W.K. Kellogg (InsiderMonkey, FY2025).
  • AgsoNovel — Lazard noted on a $25bn combination with Axcelta in earnings collateral (InsiderMonkey, Q4 2025).
  • Atlas Holdings / ODP — Lazard advised on Atlas Holdings’ $1bn acquisition of ODP (InsiderMonkey, Q4 2025).
  • Axcelta — Lazard cited on the AgsoNovel–Axcelta combination (InsiderMonkey, Q4 2025).
  • Calpine — Lazard noted in discussion of Constellation Energy’s acquisition of Calpine (InsiderMonkey, Q4 2025).
  • Cognizant (CTSH) — Lazard referenced on Three Clouds acquisition by Cognizant (InsiderMonkey, Q4 2025).
  • First Brands Group — Lazard engaged on liability management and restructuring for First Brands Group (InsiderMonkey, Q4 2025).
  • Invest Industrial — Lazard involved in Invest Industrial’s acquisition activity including TreeHouse Foods (InsiderMonkey, Q4 2025).
  • Kellanova (duplicate) — Kellanova sale to Mars referenced in Lazard materials (InsiderMonkey, Q4 2025).
  • MotiveCare — Lazard involved in creditor roles for MotiveCare in restructuring (InsiderMonkey, Q4 2025).
  • Next Wind — Lazard worked on capital structure and debt raising for Next Wind (InsiderMonkey, Q4 2025).
  • ODP Corporation (duplicate) — See Atlas Holdings/ODP advisory mention (InsiderMonkey, Q4 2025).
  • Pine Gate Renewables — Lazard engaged on debtor restructuring assignments including Pine Gate (InsiderMonkey, Q4 2025).
  • SACS Global — Lazard involved in creditor restructuring roles for SACS Global (InsiderMonkey, Q4 2025).
  • SI Group — Lazard listed on creditor roles in restructuring (InsiderMonkey, Q4 2025).
  • Three Clouds — Lazard noted for Three Clouds acquisition by Cognizant (InsiderMonkey, Q4 2025).
  • VIR (duplicate) — Vir Biotechnology listing confirmed in PR filings (PR Newswire, FY2026).
  • CVCCF / CVC Capital Partners (duplicate) — See CVC advisory references (InsiderMonkey, Q4 2025).
  • THS / TreeHouse Foods (duplicate) — See Invest Industrial transaction (InsiderMonkey, FY2026).
  • Reata Pharmaceuticals (duplicate) — See Biogen acquisition mention (CityBiz, FY2024).
  • Alpine Immune Sciences (duplicate) — See Vertex transaction (CityBiz, FY2024).
  • Boston Celtics (duplicate) — See Sixth Street consortium listing (InsiderMonkey, FY2025).
  • Galderma (duplicate) — See CityBiz healthcare roster (FY2024).
  • CymaBay Therapeutic (duplicate) — See Gilead acquisition mention (CityBiz, FY2024).
  • (Final duplicates and lower‑match entries are captured above per their source citations and fiscal‑period notes.)

Investment implications and headline risks

  • Revenue lumpy, fee‑driven: Advisory mandates generate outsized fees when closed; failure to convert pipeline creates near‑term downside.
  • Short contract tenor increases churn risk but broad client base and global footprint limit single‑client concentration (company filings, FY2024).
  • Restructuring and sovereign advisory expertise positions Lazard countercyclically in stressed markets, offsetting weak M&A periods.
  • Operational signal: Lazard’s client roster demonstrates breadth across industries and deal types, reinforcing the firm’s strategy of diversified advisory revenue rather than dependence on recurring long‑term contracts.

For a structured view of Lazard’s client relationships and to map mandate flow against financials, explore our portal at https://nullexposure.com/.

Key takeaway: Lazard is a high‑touch, fee‑for‑results franchise—exposure to deal cycles is the dominant stock risk, while diversified global clients and immaterial concentration are steady offsets.

Join our Discord